Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Print publication year: 2010
  • Online publication date: August 2011

Chapter 17 - In vitro maturation of oocytes

from Section 5: - Alternatives to ovarian hyperstimulation
Export citation
Summary
Management of the poor responder remains one of the greatest challenges of controlled ovarian hyperstimulation (COH) in preparation for the assisted reproductive technologies. This chapter reviews a variety of approaches which have been employed in this poorly defined patient group. The profound suppression of gonadotropins induced by traditional long luteal gonadotropin-releasing hormone agonist (GnRHa) protocols may be particularly devastating for poor responders. Decreasing the GnRHa dose during the luteal phase prior to COH would theoretically decrease the extent of endogenous gonadotropin suppression while preventing premature ovulation. The administration of estradiol in the luteal phase may induce follicle-stimulating hormone (FSH) receptor formation in more resistant follicles and result in a more coordinated gonadotropin response. The ability to enhance endogenous follicular phase gonadotropin release by the administration of either clomiphene citrate or an aromatase inhibitor would represent an attractive adjunct to GnRHant protocols in poor-responder patients.

Keywords:

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Ovarian Stimulation
  • Online ISBN: 9780511762390
  • Book DOI: https://doi.org/10.1017/CBO9780511762390
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×

References

1. Tan SL, Royston P, Campbell S, et al. Cumulative conception and livebirth rates after in-vitro fertilisation. Lancet 1992;339:1390–1394.
2. Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet 1978;2:366.
3. Hughes EG, Fedorkow DM, Daya S, et al. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888–896.
4. Tan SL, Maconochie N, Doyle P, et al. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin. Am J Obstet Gynecol 1994;171: 513–520.
5. Engmann L, Maconochie N, Bekir JS, Jacobs HS, Tan SL. Cumulative probability of clinical pregnancy and live birth after a multiple cycle IVF package: a more realistic assessment of overall and age-specific success rates? Br J Obstet Gynaecol 1999;106:165–170.
6. Ata B, Tulandi T. Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment. Expert Rev Obstet Gynecol 2009;4:299–311.
7. MacDougall MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod 1993;8:233–237.
8. Baart EB, Martini E, Eijkemans MJ, et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007;22:980–988.
9. Edwards RG. IVF, IVM, natural cycle IVF, minimal stimulation IVF – time for a rethink. Reprod Biomed Online 2007;15:106–119.
10. Martínez-Conejero JA, Simón C, Pellicer A, Horcajadas JA. Is ovarian stimulation detrimental to the endometrium? Reprod Biomed Online 2007;15:45–50.
11. Pincus G, Enzmann EV. The comparative behavior of mammalian eggs in vivo and in vitro: I. The activation of ovarian eggs. J Exp Med 1935;62:665–675.
12. Edwards RG. Maturation in vitro of human ovarian oöcytes. Lancet 1965;2:926–929.
13. Veeck LL, Wortham JW Jr, Witmyer J, et al. Maturation and fertilization of morphologically immature human oocytes in a program of in vitro fertilization. Fertil Steril 1983;39:594–602.
14. Cha KY, Koo JJ, Ko JJ, et al. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril 1991;55:109–113.
15. Trounson A, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril 1994;62:353–362.
16. Chian RC, Gülekli B, Buckett WM, Tan SL. Priming with human chorionic gonadotropin before retrieval of immature oocytes in women with infertility due to the polycystic ovary syndrome. N Engl J Med 1999;341:1624, 1626.
17. Chian RC, Buckett WM, Tulandi T, Tan SL. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod 2000;15:165–170.
18. Tan SL, Child TJ, Gulekli B. In vitro maturation and fertilization of oocytes from unstimulated ovaries: predicting the number of immature oocytes retrieved by early follicular phase ultrasonography. Am J Obstet Gynecol 2002;186:684–689.
19. Son WY, Chung JT, Herrero B, et al. Selection of the optimal day for oocyte retrieval based on the diameter of the dominant follicle in hCG-primed in vitro maturation cycles. Hum Reprod 2008;23:2680–2685.
20. Chian RC, Buckett WM, Abdul Jalil AK, et al. Natural-cycle in vitro fertilization combined with in vitro maturation of immature oocytes is a potential approach in infertility treatment. Fertil Steril 2004;82:1675–1678.
21. Wynn P, Picton HM, Krapez JA, et al. Pretreatment with follicle stimulating hormone promotes the numbers of human oocytes reaching metaphase II by in-vitro maturation. Hum Reprod 1998;13:3132–3138.
22. Son WY, Yoon SH, Lim JH. Effect of gonadotrophin priming on in-vitro maturation of oocytes collected from women at risk of OHSS. Reprod Biomed Online 2006;13:340–348.
23. Fadini R, Dal Canto MB, Mignini Renzini M, et al. Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study. Reprod Biomed Online 2009;19:343–351.
24. Mikkelsen AL, Smith SD, Lindenberg S. In-vitro maturation of human oocytes from regularly menstruating women may be successful without follicle stimulating hormone priming. Hum Reprod 1999;14:1847–1851.
25. Mikkelsen AL, Lindenberg S. Benefit of FSH priming of women with PCOS to the in vitro maturation procedure and the outcome: a randomized prospective study. Reproduction 2001;122:587–592.
26. Gulekli B, Buckett WM, Chian RC, et al. Randomized, controlled trial of priming with 10,000 IU versus 20,000 IU of human chorionic gonadotropin in women with polycystic ovary syndrome who are undergoing in vitro maturation. Fertil Steril 2004;82:1458–1459.
27. Son WY, Chung JT, Chian RC, et al. A 38 h interval between hCG priming and oocyte retrieval increases in vivo and in vitro oocyte maturation rate in programmed IVM cycles. Hum Reprod 2008;23:2010–2016.
28. Son WY, Chung JT, Demirtas E, et al. Comparison of in-vitro maturation cycles with and without in-vivo matured oocytes retrieved. Reprod Biomed Online 2008;17:59–67.
29. Son WY, Lee SY, Lim JH. Fertilization, cleavage and blastocyst development according to the maturation timing of oocytes in in vitro maturation cycles. Hum Reprod 2005;20:3204–3207.
30. Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. Hum Reprod Update 2003;9:515–522.
31. Isaacs JD Jr, Wells CS, Williams DB, et al. Endometrial thickness is a valid monitoring parameter in cycles of ovulation induction with menotropins alone. Fertil Steril 1996;65:262–266.
32. Khalifa E, Brzyski RG, Oehninger S, Acosta AA, Muasher SJ. Sonographic appearance of the endometrium: the predictive value for the outcome of in-vitro fertilization in stimulated cycles. Hum Reprod 1992;7:677–680.
33. Söderström-Anttila V, Mäkinen S, Tuuri T, Suikkari AM. Favourable pregnancy results with insemination of in vitro matured oocytes from unstimulated patients. Hum Reprod 2005;20:1534–1540.
34. Child TJ, Gulekli B, Sylvestre C, Tan SL. Ultrasonographic assessment of endometrial receptivity at embryo transfer in an in vitro maturation of oocyte program. Fertil Steril 2003;79:656–658.
35. Navot D, Bergh PA, Williams M, et al. An insight into early reproductive processes through the in vivo model of ovum donation. J Clin Endocrinol Metab 1991;72:408–414.
36. Child TJ, Abdul-Jalil AK, Gulekli B, Tan SL. In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome. Fertil Steril 2001;76:936–942.
37. Elizur SE, Son WY, Yap R, et al. Comparison of low-dose human menopausal gonadotropin and micronized 17beta-estradiol supplementation in in vitro maturation cycles with thin endometrial lining. Fertil Steril 2009;92:907–912.
38. Nagy ZP, Cecile J, Liu J, et al. Pregnancy and birth after intracytoplasmic sperm injection of in vitro matured germinal-vesicle stage oocytes: case report. Fertil Steril 1996;65:1047–1050.
39. Oren-Benaroya R, Orvieto R, Gakamsky A, Pinchasov M, Eisenbach M. The sperm chemoattractant secreted from human cumulus cells is progesterone. Hum Reprod 2008;23:2339–2345.
40. Holzer H. World status of babies born through IVM. Proceedings of the 1st European Congress on In Vitro Maturation of Human Oocytes in assisted reproduction 2008.
41. Buckett WM, Chian RC, Holzer H, et al. Obstetric outcomes and congenital abnormalities after in vitro maturation, in vitro fertilization, and intracytoplasmic sperm injection. Obstet Gynecol 2007;110:885–891.
42. Son WY, Lee SY, Yoon SH, Lim JH. Pregnancies and deliveries after transfer of human blastocysts derived from in vitro matured oocytes in in vitro maturation cycles. Fertil Steril 2007;87:1491–1493.
43. Chian RC, Buckett WM, Tan SL. In-vitro maturation of human oocytes. Reprod Biomed Online 2004;8:148–166.
44. Buckett WM, Chian RC, Dean NL, et al. Pregnancy loss in pregnancies conceived after in vitro oocyte maturation, conventional in vitro fertilization, and intracytoplasmic sperm injection. Fertil Steril 2008;90:546–550.
45. Homburg R. Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab 2006;20:281–292.
46. Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993;8:959–964.
47. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997;3:359–365.
48. Cha KY, Chung HM, Lee DR, et al. Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. Fertil Steril 2005;83:1461–1465.
49. Söderström-Anttila V, Salokorpi T, Pihlaja M, Serenius-Sirve S, Suikkari AM. Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes. Hum Reprod 2006;21:1508–1513.
50. Mikkelsen AL. Strategies in human in-vitro maturation and their clinical outcome. Reprod Biomed Online 2005;10:593–599.
51. Gosden R, Trasler J, Lucifero D, Faddy M. Rare congenital disorders, imprinted genes, and assisted reproductive technology. Lancet 2003;361:1975–1977.
52. Bonduelle M, Van Assche E, Joris H, et al. Prenatal testing in ICSI pregnancies: incidence of chromosomal anomalies in 1586 karyotypes and relation to sperm parameters. Hum Reprod 2002;17:2600–2614.
53. Koivurova S, Hartikainen AL, Gissler M, et al. Neonatal outcome and congenital malformations in children born after in-vitro fertilization. Hum Reprod 2002;17:1391–1398.
54. Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med 2002;346:725–730.
55. McDonald SD, Murphy K, Beyene J, Ohlsson A. Perinatal outcomes of singleton pregnancies achieved by in vitro fertilization: a systematic review and meta-analysis. J Obstet Gynaecol Can 2005;27:449–459.
56. Shu-Chi M, Jiann-Loung H, Yu-Hung L, et al. Growth and development of children conceived by in-vitro maturation of human oocytes. Early Hum Dev 2006;82:677–682.
57. Lim KS, Yoon SH, Lim JH. IVM as an alternative for over-responders. In: Tan SL, Chian RC, Buckett W, eds. In Vitro Maturation of Human Oocytes. London: Informa; 2007:Chapter 23.
58. Liu J, Lu G, Qian Y, Mao Y, Ding W. Pregnancies and births achieved from in vitro matured oocytes retrieved from poor responders undergoing stimulation in in vitro fertilization cycles. Fertil Steril 2003;80:447–449.
59. Liu J, Lim JH, Chian RC. IVM as an alternative for poor responders. In: Tan SL, Chian RC, Buckett W, eds. In Vitro Maturation of Human Oocytes. London: Informa Healthcare; 2007:333–344.
60. Child TJ, Gulekli B, Chian RC, Abdul-Jalil AK, Tan SL. In-vitro maturation (IVM) of oocytes from unstimulated normal ovaries of women with a previous poor response to IVF. Fertil Steril 2000;74 Suppl 1: S4s.
61. The American Society for Reproductive Medicine. Guidelines for oocyte donation. Fertil Steril 2004;82:13–15.
62. Remohí J, Gartner B, Gallardo E, et al. Pregnancy and birth rates after oocyte donation. Fertil Steril 1997;67:717–723.
63. Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 2009;338:b249.
64. Holzer H, Scharf E, Chian RC, et al. In vitro maturation of oocytes collected from unstimulated ovaries for oocyte donation. Fertil Steril 2007;88:62–67.
65. Gidoni Y, Holzer H, Tulandi T, Tan SL. Fertility preservation in patients with non-oncological conditions. Reprod Biomed Online 2008;16:792–800.
66. Elizur SE, Chian RC, Pineau CA, et al. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford) 2008;47:1506–1509.
67. Elizur SE, Chian RC, Holzer HE, et al. Cryopreservation of oocytes in a young woman with severe and symptomatic endometriosis: a new indication for fertility preservation. Fertil Steril 2009;91:293.e1–293.e3.
68. Huang JY, Buckett WM, Gilbert L, Tan SL, Chian RC. Retrieval of immature oocytes followed by in vitro maturation and vitrification: a case report on a new strategy of fertility preservation in women with borderline ovarian malignancy. Gynecol Oncol 2007;105:542–544.
69. Huang JY, Tulandi T, Holzer H, et al. Cryopreservation of ovarian tissue and in vitro matured oocytes in a female with mosaic Turner syndrome: Case Report. Hum Reprod 2008;23:336–339.
70. Lau NM, Huang JY, MacDonald S, et al. Feasibility of fertility preservation in young females with Turner syndrome. Reprod Biomed Online 2009;18:290–295.
71. Lee SJ, Schover LR, Partridge AH, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–2931.
72. The American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005;83:1622–1628.
73. Rao GD, Chian RC, Son WS, Gilbert L, Tan SL. Fertility preservation in women undergoing cancer treatment. Lancet 2004;363:1829–1830.
74. Demirtas E, Elizur SE, Holzer H, et al. Immature oocyte retrieval in the luteal phase to preserve fertility in cancer patients. Reprod Biomed Online 2008;17:520–523.
75. Huang JY, Chen HY, Tan SL, Chian RC. Effect of choline-supplemented sodium-depleted slow freezing versus vitrification on mouse oocyte meiotic spindles and chromosome abnormalities. Fertil Steril 2007;88:1093–1100.
76. Huang JY, Chen HY, Park JY, Tan SL, Chian RC. Comparison of spindle and chromosome configuration in in vitro- and in vivo-matured mouse oocytes after vitrification. Fertil Steril 2008;90:1424–1432.
77. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006;86:70–80.
78. Katayama KP, Stehlik J, Kuwayama M, Kato O, Stehlik E. High survival rate of vitrified human oocytes results in clinical pregnancy. Fertil Steril 2003;80: 223–224.
79. Cobo A, Kuwayama M, Pérez S, et al. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. Fertil Steril 2008;89:1657–1664.
80. Chian RC, Huang JY, Gilbert L, et al. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertil Steril 2009;91:2391–2398.
81. Huang JY, Tulandi T, Holzer H, Tan SL, Chian RC. Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril 2008;89:567–572.
82. Ao A, Jin S, Rao D, et al. First successful pregnancy outcome after preimplantation genetic diagnosis for aneuploidy screening in embryos generated from natural-cycle in vitro fertilization combined with an in vitro maturation procedure. Fertil Steril 2006;85:1510–1511.
83. Abdul-Jalil AK, Child TJ, Phillips S, et al. Ongoing twin pregnancy after ICSI of PESA-retrieved spermatozoa into in-vitro matured oocytes: case report. Hum Reprod 2001;16:1424–1426.
84. Hourvitz A, Maman E, Brengauz M, Machtinger R, Dor J. In vitro maturation for patients with repeated in vitro fertilization failure due to “oocyte maturation abnormalities”. Fertil Steril 2010;94: 496–501.
85. Al-Sunaidi M, Tulandi T, Holzer H, et al. Repeated pregnancies and live births after in vitro maturation treatment. Fertil Steril 2007;87:1212.e9–e12.
Cancel
Confirm
×